Aquestive Therapeutics (AQST) Current Deferred Revenue (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Current Deferred Revenue of $20.2 million for Q1 2026, down 2.8% year-over-year from $20.8 million in Q1 2025, and up 1750.73% quarter-over-quarter from $1.1 million in Q4 2025.
Aquestive Therapeutics (AQST) Current Deferred Revenue (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $20.2 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 2.8% year-over-year to $20.2 million; the TTM figure through Mar 2026 stood at $20.2 million (down 2.8% YoY), while the FY2025 annual figure was $1.1 million, down 94.81% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $20.2 million, up from $1.1 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $37.8 million in Q1 2023, with the low at $774000.0 in Q3 2022.
- The 5-year median for Current Deferred Revenue is $20.2 million (2026), against an average of $13.8 million.
- The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue surged 2264.23% in 2023, then plunged 94.81% in 2025.
- Aquestive Therapeutics' Current Deferred Revenue stood at $1.5 million in 2022, then climbed by 2.51% to $1.6 million in 2023, then surged by 1257.38% to $21.1 million in 2024, then slumped by 94.81% to $1.1 million in 2025, then jumped by 1750.73% to $20.2 million in 2026.
- Business Quant data shows AQST's Current Deferred Revenue at $20.2 million in Q1 2026, $1.1 million in Q4 2025, and $20.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Aquestive Therapeutics | 551.85 Mn | 551.85 Mn | 9.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.94 Mn |
| Mar 31, 2026 | 20.21 Mn |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | 20.76 Mn |
| Jun 30, 2025 | 21.03 Mn |
| Mar 31, 2025 | 20.79 Mn |
| Dec 31, 2024 | 21.05 Mn |
| Sep 30, 2024 | 21.31 Mn |
| Jun 30, 2024 | 22.80 Mn |
| Mar 31, 2024 | 33.51 Mn |
| Dec 31, 2023 | 1.55 Mn |
| Sep 30, 2023 | 2.64 Mn |
| Jun 30, 2023 | 3.99 Mn |
| Mar 31, 2023 | 37.80 Mn |
| Dec 31, 2022 | 1.51 Mn |
| Sep 30, 2022 | 774,000.00 |
| Jun 30, 2022 | 1.60 Mn |
| Mar 31, 2022 | 1.60 Mn |
| Dec 31, 2021 | 765,000.00 |
| Sep 30, 2021 | 767,000.00 |